Oncogenic BRAF and p53 Interplay in Melanoma Cells and the Effects of the HDAC Inhibitor ITF2357 (Givinostat)
Oncogenic BRAF mutations have been widely described in melanomas and promote tumour progression and chemoresistance. We previously provided evidence that the HDAC inhibitor ITF2357 (Givinostat) targets oncogenic BRAF in SK-MEL-28 and A375 melanoma cells. Here, we show that oncogenic BRAF localises t...
Main Authors: | Adriana Celesia, Marzia Franzò, Diana Di Liberto, Marianna Lauricella, Daniela Carlisi, Antonella D’Anneo, Antonietta Notaro, Mario Allegra, Michela Giuliano, Sonia Emanuele |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/24/11/9148 |
Similar Items
-
The Histone Deacetylase Inhibitor ITF2357 (Givinostat) Targets Oncogenic BRAF in Melanoma Cells and Promotes a Switch from Pro-Survival Autophagy to Apoptosis
by: Adriana Celesia, et al.
Published: (2022-08-01) -
Analysis of Givinostat/ITF2357 Treatment in a Rat Model of Neonatal Hypoxic-Ischemic Brain Damage
by: Paulina Pawelec, et al.
Published: (2022-07-01) -
HDAC inhibitor ITF2357 reduces resistance of mutant-KRAS non-small cell lung cancer to pemetrexed through a HDAC2/miR-130a-3p-dependent mechanism
by: Jian Cui, et al.
Published: (2023-02-01) -
The Novel SSTR3 Agonist ITF2984 Exerts Antimitotic and Proapoptotic Effects in Human Non-Functioning Pituitary Neuroendocrine Tumor (NF-PitNET) Cells
by: Genesio Di Muro, et al.
Published: (2024-03-01) -
Estructuración de un Modelo de Vinculación en el Instituto Superior Tecnológico de Formación Profesional Administrativa y Comercial (ITF). Experiencia en el Centro Sicoterapéutico CETAD en Guayaquil, Provincia del Guayas
by: Lissette Juleysi Vacacela Conforme, Ing., et al.
Published: (2019-08-01)